Lantheus is a radiopharmaceutical company whose products pair targeting molecules with radioactive isotopes to image or treat disease. Its peptide-based work centers on somatostatin-receptor imaging for neuroendocrine tumors, where a labeled analog lights up receptor-positive lesions on a PET scan.
The company's LNTH-2501, a gallium-68 edotreotide PET diagnostic kit for somatostatin-receptor-positive neuroendocrine tumors in adults and children, drew an FDA complete response letter on June 26, 2026. The agency tied the decision to unresolved inspection conditions at the third-party facility that manufactures the drug product and could not act by the June 29 PDUFA date; it raised no concerns about the clinical data, safety, or efficacy. CEO Mary Anne Heino said the feedback related solely to the contract manufacturer, not the product's performance.
Stories here cover Lantheus's pipeline, regulatory milestones, and its position in the peptide-radioligand market. See #radiopharmaceutical, #edotreotide, #neuroendocrine-tumors, and #somatostatin.
On June 26, Lantheus disclosed a complete response letter for LNTH-2501, its gallium-68 edotreotide PET diagnostic kit for locating somatostatin-receptor-positive neuroendocrine tumors in adults and children. The FDA cited unresolved inspection conditions at the third-party facility that manufactures the drug product and could not approve by the June 29 PDUFA date. The agency raised no concerns about the clinical data, safety, or efficacy. CEO Mary Anne Heino said the feedback 'relates solely to our third-party manufacturer, and not to the clinical performance of the product.'
Lantheus's lutetium-177 dotatate ANDA (PNT2003), the first radioequivalent to Novartis's Lutathera, received FDA tentative approval on March 2, 2026; full approval is gated by the expiration of the 30-month Hatch-Waxman stay in June 2026. PNT2003 would launch into the gastroenteropancreatic neuroendocrine-tumor (GEP-NET) market alongside Lutathera and ahead of ITM-11 (Lu-edotreotide-177), which carries an August 28 PDUFA. Lantheus licensed PNT2003 from POINT Biopharma in December 2022, before Lilly's POINT acquisition.
Lantheus's PNT2003 (lutetium Lu 177 dotatate ANDA-route radioequivalent) is positioned to enter its final FDA approval window after the 30-month regulatory stay expires in June 2026. The product would be the second SSTR2 PRRT in the US neuroendocrine tumor market alongside Novartis's Lutathera, which has held the category since 2018. The regulatory framework: PNT2003 received tentative approval March 2; PYLARIFY TruVu (piflufolastat F 18) high-throughput PSMA PET formulation approved March 6. ITM's Lu-edotreotide-177 (ITM-11) follows on a separate August 28, 2026 PDUFA, and Crinetics' CRN09682 SSTR2 non-peptide drug conjugate is in Phase 1/2 BRAVESST2 — making 2026 a defining year for the SSTR2 PRRT competitive frame.